Pregnancy History and Sex of Red Cell Donors Does Not Increase Mortality Risk for...
Previous research has suggested that receipt of a red blood cell (RBC) transfusion from a female donor who has ever been pregnant increases mortality...
Early Vena Cava Filter Placement Fails to Reduce Embolic Risk in Severely Injured Patients
Placement of an inferior vena cava (IVC) filter in patients with a contraindication to prophylactic anticoagulation who have recently been admitted to the hospital...
Voxelotor Increases Hemoglobin, Decreases Hemolysis in Patients With Sickle Cell Disease
A report from the phase III HOPE trial found that once-daily voxelotor led to greater increases in hemoglobin (Hb) levels and larger reductions in...
Evaluating Risk of Developing Second Cancers in Patients With Ph-Negative Myeloproliferative Neoplasms
According to results from a nested case-control study, patients with Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms (MPNs) are at an increased risk of developing secondary...
Adding Pneumatic Compression to Heparin Therapy Does Not Reduce DVT in Critically Ill Patients
According to results from the PREVENT trial, adjunctive pneumatic compression plus pharmacologic thromboprophylaxis did not lower the risk of new lower-limb deep vein thrombosis...
Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL
The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...
Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...
Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm
Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...
Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL
In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...
Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity
The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...
Current Issue
September 2019, Volume 5, Issue 11
This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.
